Investment fluctuation in Gilead Sciences (GILD) has been rife as asset firms show mixed responses. Companies such as IFM Investors Pty Ltd, Koza & Associates Inc., and Kingstone Capital Partners Texas LLC have increased their holdings in GILD, while others like Bell Bank, First Bank & Trust, and Fulton Bank N.A. have decreased their stakes. Redburn Atlantic maintains a 'buy' rating, setting a $143 Price Target (PT).
Novel stakes in GILD continue to emerge from new investors like Procyon Advisors LLC and Ferguson Wellman Capital Management Inc, while existing stakeholders further strengthen their positions. Notably, Assenagon Asset Management S.A. has reportedly $146.33 million holdings in GILD, and GILD's CFO recently sold stock worth $283,925.
GILD is enjoying a commendable market presence, with the announcement of its Global HIV Partnership and US Manufacturing Expansion sparking vitality. The firm exceeded market returns and recently received EU approval for its Twice-Yearly HIV prevention therapy. However, some are considering the company risky, pointing out alternative stocks to buy.
Gilead Sciences GILD News Analytics from Thu, 12 Jun 2025 07:00:00 GMT to Sat, 20 Sep 2025 11:28:21 GMT -
